Little Journey

# Little Journey: High-Level Overview

Little Journey is a health-tech company that builds cloud-based digital platforms to improve the experience of children and their families during medical procedures and clinical trial participation.[3] Founded in 2018 and based in London, the company addresses a critical gap in paediatric healthcare: pre-procedural anxiety and poor patient engagement in clinical trials.[3] Its core product—a mobile app and web portal—delivers personalized, procedure-specific content to young patients, reducing anxiety and improving clinical outcomes. The platform is already deployed across 49 NHS hospitals and serves both healthcare providers and life sciences organizations conducting paediatric clinical trials.[3]

Little Journey solves two interconnected problems. In hospital settings, it reduces pre-procedural anxiety through interactive digital content and virtual reality experiences, which translates to measurable clinical and financial benefits: 80% reduction in repeat scans, 67% reduction in unplanned admissions, and up to £41.38 saved per patient.[4] In the clinical trials space, it addresses recruitment and retention challenges—historically major obstacles in paediatric research—by improving patient and family engagement throughout the trial journey.[3]

# Origin Story

Little Journey was founded in 2018 by Dr. Chris Evans (Co-Founder and CEO) and Sophie Copley (Co-Founder and Chief Product Officer), with clinical and research expertise at its foundation.[2][3] Dr. Evans's background in clinical care and Sophie Copley's design expertise shaped the company's human-centered approach to digital health. The company emerged from a clear clinical need: children undergoing medical procedures experience significant anxiety, and existing solutions were inadequate.[3]

The company's evolution reflects market demand. Initially focused on reducing pre-procedural anxiety in hospital settings through virtual reality and interactive content, Little Journey expanded in 2021 into the global life sciences sector to support patient engagement in paediatric clinical trials.[3] This pivot positioned the company at the intersection of two high-value healthcare challenges, broadening its addressable market and revenue streams.

# Core Differentiators

• Clinical validation and real-world deployment: The platform operates across 49 NHS hospitals, providing evidence of clinical efficacy and regulatory acceptance.[3] Independent analysis from the York Health Economics Consortium quantifies impact: measurable reductions in repeat procedures, unplanned admissions, and per-patient costs.[4]

• Personalization at scale: The "A Little About Me" feature—a first-of-its-kind digital tool—captures children's preferences, communication needs, and potential triggers through interactive quizzes, automatically generating care profiles that clinicians can action immediately.[4] This transforms generic content into individualized clinical support.

• Dual revenue model: By serving both hospital systems (reducing procedural anxiety) and life sciences companies (improving clinical trial recruitment and retention), Little Journey diversifies revenue and reduces dependency on any single customer segment.[3]

• Accessibility focus: The company has established an Accessibility Centre of Excellence dedicated to improving product usability for neurodivergent children and users with disabilities, addressing an underserved population.[5]

• Data-driven design: The platform is explicitly built on data and centered around families, enabling continuous product refinement based on real-world usage patterns.[4]

# Role in the Broader Tech Landscape

Little Journey operates at the convergence of three powerful trends: digital health adoption, paediatric clinical trial modernization, and patient-centered care transformation. Healthcare systems globally are accelerating digital engagement tools to improve efficiency and outcomes, particularly post-pandemic. Simultaneously, the life sciences industry faces acute challenges in recruiting and retaining paediatric trial participants—a bottleneck that slows drug development for children. Little Journey's dual-market positioning allows it to capture value across both trends.

The company also exemplifies a broader shift in health-tech: moving beyond one-off digital tools toward integrated platforms that embed clinical workflows and generate actionable data. By proving that digital engagement reduces costs and improves outcomes in paediatric care, Little Journey influences how healthcare systems evaluate digital health investments and sets a benchmark for evidence-based health-tech adoption.

# Quick Take & Future Outlook

Little Journey is well-positioned for sustained growth. The company recently closed a £6 million Series A funding round (final close in 2025) with investors including Foresight, Mercia, Octopus Ventures, and Par Equity, alongside earlier backing from Octopus Ventures, Northern Powerhouse Investment Fund, and NHS Innovation Accelerator.[3][1] This capital will accelerate commercial expansion, strengthen marketing, and enhance the product suite—particularly international growth and clinical trial platform capabilities.

The trajectory suggests Little Journey will become a category leader in paediatric digital health. As NHS systems increasingly adopt value-based care models and life sciences companies face mounting pressure to improve trial efficiency, demand for platforms like Little Journey will intensify. The company's clinical credibility, real-world deployment scale, and accessibility focus create defensible competitive advantages. Watch for expansion into adjacent paediatric care areas (mental health support, chronic disease management) and geographic markets beyond the UK as the company matures.